The heparin market is estimated to secure a valuation of US$ 6.2 billion in 2023 and is estimated to rise to US$ 9.2 billion by 2033, as per Future Market Insights. The market is anticipated at a CAGR of 4% during the forecast period. The factors accelerating the demand for heparin are as follows-
Increasing number of accidents globally
Increasing technological advances and government investment in the healthcare sector
Advances in heparin products and increased patient awareness
Increasing prevalence of the number of surgical procedures performed
Growth of chronic diseases, injury, and increased rate of cardiovascular disorders worldwide
Rise in healthcare expenditure
High demand for anticoagulants
Increasing prevalence of Venous Thromboembolism
Increased occurrence of heart-related disorder
North America dominates the heparin market during the forecast period
The rapid increase in the number of accidents and surgeries is likely to drive the growth of the heparin market. The increasing initiatives taken by the government and rising healthcare expenditure are some of the key factors anticipated to drive the growth of the heparin market during the forecast period. Also, the rising prevalence of chronic diseases such as pulmonary embolism, cardiovascular disorders, deep vein thrombosis, and renal diseases is considered to be one of the major factors driving the overall market.
Increased research & development in the field of heparin including the development of low molecular weight heparin which has advantages over traditional heparin is expected to drive the growth of the market. Also, the increased demand for heparin products in emerging markets like Asia Pacific, Latin America, and the Middle East is expected to create new opportunities for heparin manufacturers and suppliers
North America dominates the heparin market owing to the increased incidences of cardiovascular diseases, cancer, and diabetes in the region. The increased healthcare spending and expansion of the healthcare sector are driving market growth in the region. Europe is projected to witness the fastest growth in the heparin market during the forecast period owing to the increased production of heparin in many European countries.
Asia Pacific is expected to exhibit the fastest growth in the heparin market during the forecast period owing to the expanding healthcare expenditure and increased adoption of technologically advanced products.
The key players in the heparin market are Pfizer, Aspen Holdings, Leo Pharma A/S, Sanofi, B. Braun Melsungen AG, Fresinius SE & Co, KGaA, Mylan AV, Sandoz(Novartis AG), Hikama Pharmaceuticals PLC, Bioiberica S.A.U. among others.
With the presence of such a high number of participants, the heparin market is highly competitive. The market players in the heparin market follow the strategies such as a merger, acquisitions, and R&D investments to increase their market presence. For instance, in March 2023 Aspen Healthcare, a subsidiary of Aspen Pharmacare Holdings Limited, entered into an MOU with a Saudi chemical company holding, a subsidiary of AJA pharmaceutical industry Ltd, a recognized manufacturer of pharmaceutical products
The heparin market is expected to grow significantly in the future driven by the increased demand for anticoagulant drugs due to the rising prevalence of cardiovascular diseases and the rapidly growing aging population. With the increased demand for the product new market players are entering the market with new products to fulfill the increased demand.
For instance, founded in 2015 Hepoligo solution is focused on developing heparin-based drugs & intermediates. The hepoligo also manufactures synthetic heparins which have specific therapeutic effects as an anti-tumor agent and an anti-inflammatory. They have developed scalable processes for making the anti-coagulant drug fondaparinux.
Data Points
Key Statistics
Expected Market Value in 2023
US$ 6.2 billion
Projected Market Value in 2033
US$ 9.2 billion
Growth Rate (2023 to 2033)
CAGR of 4%
Demand for heparin market will elevate in the course of forecast period while experiencing a steady growth.
Adverse effects caused by heparin such as heparin-induced thrombocytopenia is likely to have negative impact, However, Commercialization of cost-effective and safe products, with greater efficacy and lesser side effects is expected to offer new business opportunities.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What is Driving Demand for Heparin?
Heparin is widely used injectable anti-coagulant, which prevents the formation of blood clots. It has its application in pulmonary embolism, deep vein thrombosis, and other cardiovascular surgeries. High incidence of these disorders will augment the market growth.
Also, increasing number of accident cases resulting in surgeries is expected to drive the growth of heparin market across the globe. As per Association for Safe International Travel, in 2020, approximately 4.4 million individuals were severely injured and require immediate medical attention in the USA alone. This high number injuries will lead to rise in demand of anti-coagulant agents such as heparin.
Additionally, growing research and development activities, FDA approvals and new product launch, promising clinical trial pipeline, introduction of novel products will lead to the significant growth in the forecast period.
New Product Developments Likely to Augment the Heparin Sales
Needle stick injuries is one of the common hazard in hospitals, and other clinical settings, which can lead to transmission and infection of various diseases. In order to overcome this issue, various leading players are focusing on introducing ready –to administer heparin in pre-filled syringes or IV bags.
In this regard, Fresenius Kabi, in April 2021 has introduced low concentration of Heparin Sodium Injection in Ready-to-use Freeflex Bags. Its Leak resistant technology, easy handling, and patient safety are some of the benefits associated with these bags. Such benefits are expected to drive its demand among hospitals, specialty clinics, ambulatory surgical centers which are the major end users of this products.
Find your sweet spots for generating winning opportunities in this market.
USA and Canada Heparin Market Outlook
USA and Canada are among the largest market for heparin making North America a dominant player. According to the Centers of Disease Control and Prevention, an estimated 90,000 patients are affected by DVT/PE in the United States, Also, around 60,000-100,000 thousand Americans die of DVT/PE.
Also, high incidence of thrombosis is recorded in the Canada. According to Thrombosis Canada, it is estimated that approximately 45,000 patients in Canada are affected by DVT each year, with incidence of 1-2 cases per 1,000 person annually.
Such high incidence of DVT/PE will augment the sales of heparin, thus having the positive impetus on the heparin market in these region.
Europe Demand Outlook for Heparin
Pulmonary Embolism (PE) following deep vein thrombosis affects 500,000 patients annually in the European region, which is one of the key factor attributed to the demand of the heparin. Apart from this, European market is marked by the presence of various leading manufactures such as Leo Pharma A/S, Aspen Holdings, B. Braun Melsungen AG, and Teva Pharmaceuticals Industries.
The increase in production of heparin in major European Countries has Dirven the market substantially. Also, growing region specific research and developments, with focus on the improving mechanism of heparin will further aid the market growth.
Despite the positive outlook in this region, the availability and use of the other alternative anti-coagulants such as heparin such as warfarin is expected to hamper the sales of heparins in this region
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Who are the Key Manufacturers and Suppliers of Heparin?
Some of the leading manufacturers and suppliers of heparin are
Aspen Holdings
Pfizer Inc.
Leo pharma A/S
Sanofi
B. Braun Melsungen AG
Fresenius SE & Co
KGaA
Mylan, N.V.
Sandoz (Novartis AG)
Hikma Pharmaceuticals PLC
Bioiberica S.A.U.
These manufactures aim to introduce the new products which with improved safety, and accuracy of the medicines. For instance, in September 2019, Hikma Pharmaceuticals introduced Heparin Sodium prefilled syringes, USP 5000 Units/ml. Also, in April 2019, another industry major, B. Braun introduced First FDA –approved Heparin sodium pre-filled syringes.
Availability of such ready to administer products will help he healthcare provider to treat patients faster, with reduced risk of needle stick injuries.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geographies.
